513 related articles for article (PubMed ID: 18794035)
1. Utilization, price, and spending trends for antidepressants in the US Medicaid Program.
Chen Y; Kelton CM; Jing Y; Guo JJ; Li X; Patel NC
Res Social Adm Pharm; 2008 Sep; 4(3):244-57. PubMed ID: 18794035
[TBL] [Abstract][Full Text] [Related]
2. Drug Expenditure, Price, and Utilization in the U.S. Medicaid: A Trend Analysis for SSRI and SNRI Antidepressants from 1991 to 2018.
Alrasheed M; Hincapie AL; Guo JJ
J Ment Health Policy Econ; 2021 Mar; 24(1):3-11. PubMed ID: 33739932
[TBL] [Abstract][Full Text] [Related]
3. Differences in the cost of antidepressants across state Medicaid programs.
Kelton CM; Rebelein RP; Heaton PC; Ferrand Y; Guo JJ
J Ment Health Policy Econ; 2008 Mar; 11(1):33-47. PubMed ID: 18424875
[TBL] [Abstract][Full Text] [Related]
4. Utilization, spending, and price trends for benzodiazepines in the US Medicaid program: 1991-2009.
Gorevski E; Bian B; Kelton CM; Martin Boone JE; Guo JJ
Ann Pharmacother; 2012 Apr; 46(4):503-12. PubMed ID: 22454448
[TBL] [Abstract][Full Text] [Related]
5. Using time-series intervention analysis to understand U.S. Medicaid expenditures on antidepressant agents.
Ferrand Y; Kelton CM; Guo JJ; Levy MS; Yu Y
Res Social Adm Pharm; 2011 Mar; 7(1):64-80. PubMed ID: 21397882
[TBL] [Abstract][Full Text] [Related]
6. Trends in the utilization of, spending on, and prices for outpatient antifungal agents in US Medicaid programs: 1991-2009.
Desai VC; Cavanaugh TM; Kelton CM; Guo JJ; Heaton PC
Clin Ther; 2012 Oct; 34(10):2118-2131.e1. PubMed ID: 23031625
[TBL] [Abstract][Full Text] [Related]
7. The cost effect of newer medication adoption in an older Medicaid cohort.
Shireman TI; Rigler SK; Jachna CM; Griebling TL; Eng ML
J Am Geriatr Soc; 2005 Aug; 53(8):1366-73. PubMed ID: 16078963
[TBL] [Abstract][Full Text] [Related]
8. Firm- and drug-specific patterns of generic drug payments by US medicaid programs: 1991-2008.
Kelton CM; Chang LV; Guo JJ; Yu Y; Berry EA; Bian B; Heaton PC
Appl Health Econ Health Policy; 2014 Apr; 12(2):165-77. PubMed ID: 24550087
[TBL] [Abstract][Full Text] [Related]
9. Long-term Medicaid excess payments from alleged price manipulation of generic lorazepam.
Bian B; Gorevski E; Kelton CM; Guo JJ; Martin Boone JE
J Manag Care Pharm; 2012 Sep; 18(7):506-15. PubMed ID: 22971204
[TBL] [Abstract][Full Text] [Related]
10. Potential savings from increased use of generic drugs in the elderly: what the experience of Medicaid and other insurance programs means for a Medicare drug benefit.
Fischer MA; Avorn J
Pharmacoepidemiol Drug Saf; 2004 Apr; 13(4):207-14. PubMed ID: 15255087
[TBL] [Abstract][Full Text] [Related]
11. Prescription analgesic and antidepressant utilization and cost among elderly Medicaid beneficiaries before and after nursing home admission.
Chu L; Schnelle JF; Osterweil D
J Am Med Dir Assoc; 2004; 5(2):75-81. PubMed ID: 14984617
[TBL] [Abstract][Full Text] [Related]
12. Association of authorized generic marketing with prescription drug spending on antidepressants from 2000 to 2011.
Cheng N; Banerjee T; Qian J; Hansen RA
J Am Pharm Assoc (2003); 2017; 57(3):341-348. PubMed ID: 28400255
[TBL] [Abstract][Full Text] [Related]
13. Trends in prescription drug expenditures by Medicaid enrollees.
Banthin JS; Miller GE
Med Care; 2006 May; 44(5 Suppl):I27-35. PubMed ID: 16625061
[TBL] [Abstract][Full Text] [Related]
14. A pharmacoeconomic study of the management of major depression: patients in a TennCare HMO.
Smith W; Sherrill A
Med Interface; 1996 Jul; 9(7):88-92. PubMed ID: 10159282
[TBL] [Abstract][Full Text] [Related]
15. The impact of unrecognized bipolar disorders among patients treated for depression with antidepressants in the fee-for-services California Medicaid (Medi-Cal) program: a 6-year retrospective analysis.
McCombs JS; Ahn J; Tencer T; Shi L
J Affect Disord; 2007 Jan; 97(1-3):171-9. PubMed ID: 16860396
[TBL] [Abstract][Full Text] [Related]
16. Extensions of intellectual property rights and delayed adoption of generic drugs: effects on medicaid spending.
Kesselheim AS; Fischer MA; Avorn J
Health Aff (Millwood); 2006; 25(6):1637-47. PubMed ID: 17102189
[TBL] [Abstract][Full Text] [Related]
17. Projecting future drug expenditures--1994.
Santell JP
Am J Hosp Pharm; 1994 Jan; 51(2):177-87. PubMed ID: 8160668
[TBL] [Abstract][Full Text] [Related]
18. Opioid expenditures and utilization in the Medicaid system.
Brixner DI; Oderda GM; Roland CL; Rublee DA
J Pain Palliat Care Pharmacother; 2006; 20(1):5-13. PubMed ID: 16687350
[TBL] [Abstract][Full Text] [Related]
19. Choice of generic versus brand-name antidepressants in a regulated prescription drug market: evidence from Taiwan.
Liu YM; Ou HT; Yang YK
J Ment Health Policy Econ; 2014 Dec; 17(4):163-72. PubMed ID: 25599280
[TBL] [Abstract][Full Text] [Related]
20. Principal components analysis of drug expenditure and utilisation trends for major therapeutic classes in US Medicaid programmes.
Guo JJ; Jing Y; Nguyen K; Fan H; Li X; Kelton CM
J Med Econ; 2008; 11(4):671-94. PubMed ID: 19450075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
